(Press-News.org) Patients with chronic kidney disease and Type 2 diabetes who took the experimental drug finerenone were about 30% less likely to develop the heart rhythm disorder atrial fibrillation (AFib) than those taking a placebo, according to data presented at the American College of Cardiology's 70th Annual Scientific Session.
Last year, researchers reported that the trial, called FIDELIO-DKD, met its primary endpoint showing a significant benefit of finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, in terms of a composite of sustained decrease in kidney function, kidney failure and renal death. The new analysis reveals that patients derived these benefits regardless of their history with AFib and suggests that taking finerenone also reduced the rate of new-onset AFib.
"Finerenone can lower the risk of development of atrial fibrillation in patients with chronic kidney disease and diabetes and can be used as a therapeutic strategy to delay its onset," said Gerasimos Filippatos, MD, from the National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital in Athens, Greece, and the study's lead author. "It can also protect the heart and the kidney from further damage caused by chronic kidney disease and diabetes in these patients with or without pre-existing atrial fibrillation."
Chronic kidney disease, diabetes and AFib are major public health concerns worldwide. Patients with chronic kidney disease and diabetes face an increased risk of developing AFib because these conditions can cause changes in the heart's structure and electric signaling, leading to fast and erratic heart rhythms. During preclinical studies, finerenone was reported to slow these structural changes.
FIDELIO-DKD randomly assigned 5,674 patients with chronic kidney disease and diabetes to take finerenone or a placebo and tracked outcomes for a median of 2.6 years. The primary endpoint was a composite of kidney failure, renal death or sustained decrease in estimated glomerular filtration rate (a measure of kidney function) of 40% or more from baseline. The key secondary outcome included death by loss of heart function, nonfatal heart attack, nonfatal stroke or hospitalization for heart failure.
As previously reported, finerenone significantly lowered the risk of kidney events by 18% and the risk of cardiovascular events by 14% compared with placebo. For the new analysis, researchers assessed outcomes among patients with and without a history of AFib or atrial flutter (about 8% of participants had AFib or atrial flutter at the start of the trial) and the risk of patients developing AFib or atrial flutter during the study.
The results found the primary and secondary endpoints were significantly lower in patients taking finerenone regardless of their AFib status at the start of the study.
"The previously-reported kidney and heart protection with finerenone applied equally to patients with and without pre-existing atrial fibrillation," Filippatos said.
In addition, new-onset AFib or atrial flutter was reported in 3.2% of patients taking finerenone and 4.5% of those taking a placebo, a significant difference in favor of finerenone.
Researchers said that previous findings from preclinical studies have suggested that finerenone may help reduce scarring and thickening of the heart tissue, possibly through its action of blocking mineralocorticoid receptors, a type of protein molecule present on many cell types in the heart and kidney that has been shown to be especially abundant in patients with AFib.
"Preventing or delaying the onset of atrial fibrillation in patients with chronic kidney disease and diabetes is particularly important since having atrial fibrillation can worsen chronic kidney disease and having diabetes can worsen atrial fibrillation symptoms," Filippatos said. "Treatment in these patients can also be challenging because they are prone to developing blood clots [which can lead to stroke] and bleeding. Finerenone has the potential to reduce the burden of atrial fibrillation in these patients."
Filippatos said that larger studies focused specifically on new-onset AFib would be needed to confirm the findings. Because participants underwent heart rhythm tests only once per year in FIDELIO-DKD, Filippatos said it is possible that researchers missed asymptomatic AFib or cases that were not apparent from tests. A separate trial is currently underway to examine finerenone's effects in patients with less severe chronic kidney disease and diabetes.
INFORMATION:
This study was simultaneously published online in the Journal of the American College of Cardiology at the time of presentation. The study was funded by Bayer AG.
Filippatos will be available to the media in a virtual press conference on Monday, May 17, at 12:15 p.m. ET / 16:15 UTC.
Filippatos will present the study, "Finerenone and New Onset of Atrial Fibrillation or Flutter in Patients with Chronic Kidney Disease and Type 2 Diabetes," on Monday, May 17, at 10:45 a.m. ET / 14:45 UTC, virtually.
ACC.21 will take place May 15-17 virtually, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC21 for the latest news from the meeting.
The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit ACC.org.
A subgroup of patients who experienced an out-of-hospital cardiac arrest (OHCA) that did not respond to standard advanced cardiac life support (ACLS), were immediately transported to a cardiac care center, and placed on a device similar to a heart-lung bypass machine were more likely to have survived with good brain function six months later than similar patients who received standard care at the site where the OHCA occurred. The study was presented at the American College of Cardiology's 70th Annual Scientific Session.
"This study--the largest randomized clinical trial that has been conducted to address this question--shows that a hyperinvasive ...
The ocean is a big place with many deep, dark mysteries. Humans have mapped no more than 20% of the sea, and explored less. Even the kelp forests of Southern California -- among the best studied patches of ocean on the planet -- hide species not yet described by science.
Now, UC Santa Barbara's Thomas Turner has published a paper in the journal Zootaxa describing four new species of sponges. These novel specimens weren't dredged from the murky depths or found on some distant seamount, but collected locally from popular dive spots. The study brings Turner's new species count to five, and the scientist believes there may be dozens yet to discover and describe along the West ...
Southern lesser galagos (Galago moholi), a species of primate that lives in southern Africa, boast big, round eyes and are so small they can fit in your hand.
A new study from an international team of scientists, however, suggests that there may be a downside to their cuteness: The trade in lesser galagos, also known as bushbabies, which some people keep as pets, may have shifted the genetics within their wild populations over the span of decades, according to the research. Those changes could undercut the ability of the critters to adapt as human farms and cities grow throughout the region.
The study was published recently in the journal Primates and ...
Alcohol appears to have an immediate--or near-immediate--effect on heart rhythm, significantly increasing the chance that an episode of atrial fibrillation (AFib) will occur, according to new data presented at the American College of Cardiology's 70th Annual Scientific Session.
The data revealed that just one glass of wine, beer or other alcoholic beverage was associated with twofold greater odds of an episode of AFib occurring within the next four hours. Among people having two or more drinks in one sitting, there was a more than threefold higher chance of experiencing AFib. Using an alcohol sensor placed on participants' ankles, which passively monitored alcohol intake, the investigators ...
As Covid-19 spread around the world, stock markets in individual countries took a major hit - yet stock markets in China where the disease first struck avoided significant falls - researchers at Lero, the Science Foundation Ireland Research Centre for Software found.
A research paper Immune or at-risk? Stock markets and the significance of the COVID-19 pandemic by a Lero team based at University of Limerick confirmed that the growth in COVID-19 cases largely explained changes in stock prices, but surprisingly did not have the same impact in China or on the global index ...
Top experts from Brigham and Women's Hospital presented outcomes from some of the most-anticipated clinical trials in cardiology at the virtual American College of Cardiology's 70th Annual Scientific Session. In four Late-Breaking Clinical Trial presentations, Brigham cardiologists shared their latest findings on strategies to prevent future cardiovascular events in at-risk patient populations, results of a randomized clinical trial of a statin drug among patients critically ill with COVID-19, and more. ...
On Sept. 9, 2018, astronomers spotted a flash from a galaxy 860 million light years away. The source was a supermassive black hole about 50 million times the mass of the sun. Normally quiet, the gravitational giant suddenly awoke to devour a passing star in a rare instance known as a tidal disruption event. As the stellar debris fell toward the black hole, it released an enormous amount of energy in the form of light.
Researchers at MIT, the European Southern Observatory, and elsewhere used multiple telescopes to keep watch on the event, labeled AT2018fyk. To their surprise, they observed that as the ...
The entire ecosystem of the planet, including humans, depends on clean water. When carbonate rock weathers, karst areas are formed, from which around a quarter of the world's population obtains its drinking water. Scientists have been studying how quickly pollutants can reach groundwater supplies in karst areas and how this could affect the quality of drinking water. An international team led by Junior Professor Dr. Andreas Hartmann of the Chair of Hydrological Modeling and Water Resources at the University of Freiburg compared the time it takes water to seep down from the surface to the subsurface with the time it takes for pollutants to decompose ...
Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on controlling the heart rhythm (using catheter ablation) and those focused on controlling the heart rate (using drugs and/or a pacemaker) showed no significant differences in terms of death from any cause or progression of heart failure, according to a study presented at the American College of Cardiology's 70th Annual Scientific Session. The trial was stopped early and, as a result, has limited statistical power to reveal differences between the two treatment approaches; however, trends observed in the study suggest the type of heart failure a patient has may influence which approach is optimal, researchers said.
Heart failure is a condition ...
Irvine, Calif., May 17, 2021 -- Greenhouse gases and aerosol pollution emitted by human activities are responsible for increases in the frequency, intensity and duration of droughts around the world, according to researchers at the University of California, Irvine.
In a study published recently in Nature Communications, scientists in UCI's Department of Civil & Environmental Engineering showed that over the past century, the likelihood of stronger and more long-lasting dry spells grew in the Americas, the Mediterranean, western and southern Africa and eastern Asia.
"There has always been natural variability in drought events around the world, but our research shows the clear human influence on drying, specifically from anthropogenic aerosols, carbon dioxide and other ...
